The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial
Open accessAbstract
Background: Pyoderma gangrenosum (PG) is a chronic ulcerating skin condition that often occurs in association with inflammatory bowel disease. There have been a number of reports of PG responding to infliximab, a monoclonal antibody against tumour necrosis factor α. Aim: In the first randomised placebo controlled trial of any drug for the treatment of PG, we have studied the role of infliximab in this disorder. Subjects: Patients 18 years of age or older with a clinical diagnosis of PG were invited to take part. Methods: Patients were randomised to receive an infusion of infliximab at 5 mg/kg or placebo at week 0. Patients were then assessed at week 2 and non-responders were offered open labelled infliximab. The primary end point was clinical improvement at week 2, with secondary end points being remission and improvement at week 6. Results: Thirty patients were entered into the study. After randomisation, 13 patients received infliximab and 17 patients received placebo. At week 2, significantly more patients in the infliximab group had improved (46% (6/13)) compared with the placebo group (6% (1/17); p = 0.025). Overall, 29 patients received infliximab with 69% (20/29) demonstrating a beneficial clinical response. Remission rate at week 6 was 21% (6/29). There was no response in 31% (9/29) of patients. Conclusions: This study has demonstrated that infliximab at a dose of 5 mg/kg is superior to placebo in the treatment of PG. Open label treatment with infliximab also produced promising results. Infliximab treatment should be considered in patients with PG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
Chaudhari, U., Romano, P., Mulcahy, L., Dooley, L., Baker, D., & Gottlieb, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04954-0 · Cited by 890
Infliximab for the treatment of fistulas in patients with Crohn's disease
Ricart, E., & Sandborn, W. J. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70414-2 · Cited by 519
Pyoderma Gangrenosum: A Review of 86 Patients
(1985) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a067865 · Cited by 445
Optimizing anti-TNF treatment in inflammatory bowel disease
Rutgeerts, P., van Assche, G., & Vermeire, S. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.070 · Cited by 429
Bennett, M. L., Jackson, J. M., Jorizzo, J. L., Fleischer, A. B., White, W. L., & Callen, J. P. (2000) · Medicine · doi:10.1097/00005792-200001000-00004 · Cited by 404
Pyoderma gangrenosum: a report of 44 cases with follow-up
Driesch, P. V. D. (1997) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1997.20022083.x · Cited by 319
Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease
Regueiro, M. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00430-1 · Cited by 221
Cited by
Kornbluth, A., & Sachar, D. B. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,023
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910
Extraintestinal Manifestations of Inflammatory Bowel Disease
Vavricka, S. R., Schoepfer, A., Scharl, M., Lakatos, P. L., Navarini, A., & Rogler, G. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000392 · Cited by 909
Van Assche, G., Dignass, A., Reinisch, W., van der Woude, C. J., Sturm, A., De Vos, M., Guslandi, M., Oldenburg, B., Dotan, I., Marteau, P., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.09.009 · Cited by 894
Evidence-based clinical practice guidelines for inflammatory bowel disease
Matsuoka, K., Kobayashi, T., Ueno, F., Matsui, T., Hirai, F., Inoue, N., Kato, J., Kobayashi, K., Kobayashi, K., Koganei, K., et al. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1439-1 · Cited by 698
Metadata
- Authors
- Brooklyn, T. N., Dunnill, M. G. S., Shetty, A., Bowden, J. J., Williams, J. D. L., Griffiths, C. E. M., Forbes, A., Greenwood, R., & Probert, C. S.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2005-09-27
- Volume
- 55
- Issue
- 4
- Pages
- 505-509
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2125620933
- Cited by
- 646
- References
- 15
- FWCI
- 18.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. https://app.cochat.ai/papers/10.1136/gut.2005.074815
- The paper
- Brooklyn, T. N., Dunnill, M. G. S., Shetty, A., Bowden, J. J., Williams, J. D. L., Griffiths, C. E. M., Forbes, A., Greenwood, R., & Probert, C. S. (2006). Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. https://doi.org/10.1136/gut.2005.074815
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.